Year: 2025

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, including glioblastoma (GBM) and 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free Expanded pipeline with INB-600 platform, featuring novel gamma-delta T Cell engager (TCE) targeting CD19 for potential use in oncology and autoimmune diseases Continued operational execution with strengthened strategic focus on aligning resources in an effort to drive high-impact programs forward Maintaining cash position to support operations and achievement of anticipated development milestones throughout 2025 and into 2026NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported...

Zumiez Inc. Announces Fiscal 2024 Fourth Quarter Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Fourth Quarter Comparable Sales Increased 5.9%Fourth Quarter Gross Margin Increased 190 Basis Points to 36.2%Fourth Quarter Earnings Per Share Improved to $0.78 from ($1.73)First Quarter-To-Date Comparable Sales up 4.3%, Led by North America Up 6.4%Board Approves New Stock Repurchase Authorization LYNNWOOD, Wash., March 13, 2025 (GLOBE NEWSWIRE) — Zumiez Inc. (NASDAQ: ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the fourth quarter and year ended February 1, 2025. Net sales for the fourth quarter ended February 1, 2025 (13 weeks) decreased 0.9% to $279.2 million from $281.8 million in the fourth quarter ended February 3, 2024 (14 weeks). Comparable sales for the thirteen weeks ended February 1, 2025 increased 5.9%. Net income in the fourth...

Karat Packaging Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

— Robust Growth, Including Record Full Year Gross Margin, as Business Continues to Expand — CHINO, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat” or the “Company”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 HighlightsNet sales of $101.6 million, up 6.3 percent, from $95.6 million in the prior-year quarter. Gross profit of $39.8 million, up 16.8 percent, from $34.1 million in prior-year quarter. Gross margin of 39.2 percent versus 35.7 percent in the prior-year quarter. Net income of $5.9 million, up 40.3 percent, from $4.2 million in the prior-year quarter. Net income margin of 5.8 percent versus...

HF Foods Reports Fourth Quarter and Full Year 2024 Financial Results

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Net Revenue Increased 8.7% and 4.6% for the Fourth Quarter and Full Year 2024, Respectively Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) — HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” or the “Company”), a leading food distributor to Asian restaurants across the United States, reported its unaudited financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial ResultsNet revenue increased 8.7% to $305.3 million compared to $280.9 million in the prior year period. Gross profit decreased 0.2% to $52.2 million compared to $52.3 million in the prior year period. Gross profit margin decreased to 17.1% from 18.6% in the prior year period. Net loss of $43.9 million, mainly due to goodwill impairment of $46.3 million,...

Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024 Conference call and webcast to be held today at 4:30 p.m. ET SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the fourth quarter and full year ended December 31, 2024,...

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Written by Customer Service on March 13, 2025. Posted in Earnings Releases And Operating Results.

Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient Enrollment Lymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025 Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027ALLO-329 in Autoimmune Disease (AID)Secured Investigational New Drug (IND) FDA Clearance for the RESOLUTION Basket Trial in Rheumatology Trial Initiation Targeted for Mid-2025; Proof-of-Concept Data Expected Around YE 2025ALLO-316 in Renal Cell Carcinoma (RCC)Presented Positive Phase 1 Data Highlighting Meaningful Response Rates in Patients with Advanced Renal Cell Carcinoma and the Potential of the CD70 Dagger® Technology...

Blum Holdings Inc. Releases 2024 Annual Report: Executive Summary

Written by Customer Service on March 13, 2025. Posted in Public Companies.

DOWNEY, Calif., March 13, 2025 (GLOBE NEWSWIRE) — Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company and cannabis operator, is proud to announce the release of its “2024 Annual Report: Executive Summary”. “The Executive Summary highlights Blüm’s significant financial and operational transformation over the past year,” said Sabas Carrillo, Chief Executive Officer of Blüm Holdings. “Through strategic restructuring, substantial debt reduction, and a disciplined focus on core operations, we have meaningfully strengthened our financial foundation. Despite ongoing industry challenges, we believe our ability to streamline operations, optimize our asset portfolio, and enhance financial efficiency has positioned us for long-term growth. Additionally,...

Availability of the 2024 Universal Registration Document

Written by Customer Service on March 13, 2025. Posted in Public Companies.

PRESS RELEASE March 13, 2025Availability of the 2024 Universal Registration Document Boulogne-Billancourt, March 13, 2025 – Renault announces that the 2024 Universal Registration Document (in French version) has been filed, in ESEF format, with the French Financial Markets Authority (Autorité des Marchés Financiers – AMF), on March 13, 2025. The 2024 Universal Registration Document includes, inter alia:the Annual Financial Report for the 2024 financial year which notably includes:the Board of Directors’ report on corporate governance sustainability information, the certification report on sustainability information,the Statutory Auditors’ reports and information on their fees, the description of the share buy-back programme,The 2024 Universal Registration Document (French version) is available on Renault...

Caisse Française de Financement Local: TAP EMTN 2018-7 E

Written by Customer Service on March 13, 2025. Posted in Public Companies.

Paris, 13 March 2025 Capitalised terms used herein shall have the meaning specified for such terms in the Caisse Française de Financement Local base prospectus to the €75,000,000,000 Euro Medium Term Note Programme dated 8 July 2024 (the “Base Prospectus”). Caisse Française de Financement Local has decided to issue on 17 March 2025– Euro 150,000,000 Fixed Rate Obligations Foncières due 28 June 2038 to be assimilated upon listing and form a single series with the existing Euro 500,000,000 issued on 28 June 2018, the existing Euro 150,000,000 issued on 1 February 2019, the existing Euro 150,000,000 issued on 14 May 2019 and the existing Euro 100,000,000 issued on 12 February 2024. The Base Prospectus dated 8 July 2024 and the supplements to the Base Prospectus dated 13 September 2024, 30 September 2024, 26 December 2024 and 27 February...

ICON Energy Corp. Announces Receipt of Nasdaq Notice and Reminds Shareholders of its Upcoming 2025 Annual General Meeting

Written by Customer Service on March 13, 2025. Posted in Public Companies.

ATHENS, Greece, March 13, 2025 (GLOBE NEWSWIRE) — Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company that provides worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, announced today that it has received a written notification from The Nasdaq Stock Market (“Nasdaq”) dated March 7, 2025, indicating that because the closing bid price of the Company’s common shares for 30 consecutive trading days, from January 23, 2025, to March 6, 2025, was below $1.00 per share, the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2). The Company is in compliance with all other Nasdaq Capital Market continued listing standards and, pursuant to the Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance with Nasdaq...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals